$127 Million is the total value of Burrage Capital Management LLC's 27 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 19.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | Buy | EPIZYME INC | $11,960,000 | -16.4% | 1,002,528 | +12.5% | 9.44% | -5.8% |
| AIMT | AIMMUNE THERAPEUTICS INC | $11,456,000 | +106.2% | 332,546 | 0.0% | 9.04% | +132.6% | |
| MEIP | Buy | MEI PHARMA INC | $9,482,000 | -23.5% | 3,039,038 | +1.3% | 7.48% | -13.7% |
| ISEE | Buy | IVERIC BIO INC | $8,435,000 | +12.0% | 1,495,515 | +1.3% | 6.66% | +26.3% |
| PTCT | Sell | PTC THERAPEUTICS INC | $8,113,000 | -10.9% | 173,545 | -3.3% | 6.40% | +0.5% |
| KIDS | Buy | ORTHOPEDIATRICS CORP | $7,880,000 | +6.3% | 171,607 | +1.3% | 6.22% | +19.9% |
| NEO | Buy | NEOGENOMICS INC | $7,108,000 | +20.6% | 192,671 | +1.3% | 5.61% | +36.1% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $6,824,000 | +36.9% | 78,118 | +1.2% | 5.39% | +54.4% |
| CYTK | Buy | CYTOKINETICS INC | $5,734,000 | -7.0% | 264,859 | +1.3% | 4.53% | +5.0% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $5,338,000 | +28.1% | 362,383 | +41.3% | 4.21% | +44.5% |
| INSM | INSMED INC | $5,316,000 | +16.7% | 165,400 | 0.0% | 4.20% | +31.6% | |
| ANAB | Buy | ANAPTYSBIO INC | $4,876,000 | -33.5% | 330,549 | +0.7% | 3.85% | -25.0% |
| YMAB | Y-MABS THERAPEUTICS INC | $4,723,000 | -11.1% | 123,025 | 0.0% | 3.73% | +0.2% | |
| ADCT | ADC THERAPEUTICS SA | $4,451,000 | -29.5% | 134,912 | 0.0% | 3.51% | -20.5% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $3,781,000 | -8.7% | 241,278 | +2.1% | 2.98% | +3.0% |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $3,288,000 | – | 200,000 | +100.0% | 2.60% | – |
| RGNX | Buy | REGENXBIO INC | $3,203,000 | -24.4% | 116,405 | +1.2% | 2.53% | -14.7% |
| GTHX | Sell | G1 THERAPEUTICS INC | $2,640,000 | -70.9% | 228,597 | -38.9% | 2.08% | -67.2% |
| FREQ | Sell | FREQUENCY THERAPEUTICS INC | $2,577,000 | -45.6% | 134,141 | -34.2% | 2.03% | -38.7% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $2,317,000 | -4.7% | 76,804 | +3.2% | 1.83% | +7.5% |
| FULC | FULCRUM THERAPEUTICS INC | $2,313,000 | -56.6% | 291,645 | 0.0% | 1.83% | -51.1% | |
| TCDA | New | TRICIDA INC | $1,705,000 | – | 188,182 | +100.0% | 1.35% | – |
| MRUS | MERUS N V | $1,682,000 | -25.4% | 140,176 | 0.0% | 1.33% | -15.8% | |
| ZGNX | Sell | ZOGENIX INC | $703,000 | -62.8% | 39,189 | -44.0% | 0.56% | -58.0% |
| ADRO | ADURO BIOTECH INC | $330,000 | +5.1% | 135,898 | 0.0% | 0.26% | +18.6% | |
| CALT | New | CALLIDITAS THERAPEUTICS ABsponsered ads | $265,000 | – | 11,034 | +100.0% | 0.21% | – |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $175,000 | -27.4% | 15,006 | 0.0% | 0.14% | -18.3% | |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC COM | $0 | – | -156,012 | -100.0% | -2.28% | – |
| AVRO | Exit | AVROBIO INC COM | $0 | – | -225,900 | -100.0% | -2.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.